{
    "id": 3378,
    "fullName": "RET C634W",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "RET C634W lies within the extracellular domain of the Ret protein (UniProt.org). C634W results in ligand independent dimerization and constitutive activation of Ret, and is transforming in culture (PMID: 10918602, PMID: 9230192).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2272,
                    "pubMedId": 9230192,
                    "title": "Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9230192"
                },
                {
                    "id": 6879,
                    "pubMedId": 10918602,
                    "title": "A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10918602"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5979,
        "geneSymbol": "RET",
        "terms": [
            "RET",
            "CDHF12",
            "CDHR16",
            "HSCR1",
            "MEN2A",
            "MEN2B",
            "MTC1",
            "PTC",
            "RET-ELE1"
        ]
    },
    "variant": "C634W",
    "createDate": "02/26/2015",
    "updateDate": "10/22/2018",
    "referenceTranscriptCoordinates": {
        "id": 125237,
        "transcript": "NM_020975",
        "gDna": "chr10:g.43114502C>G",
        "cDna": "c.1902C>G",
        "protein": "p.C634W",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11237,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RXDX-105 (CEP-32496) reduced phosphorylation of RET and downstream signaling and inhibited proliferation of a medullary thyroid cancer cell line harboring RET C634W in culture (PMID: 28011461).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 1002,
                "therapyName": "RXDX-105",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9178,
                    "pubMedId": 28011461,
                    "title": "Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28011461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1776,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture and in cell line xenograft models (PMID: 23526464).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 312,
                    "pubMedId": 23526464,
                    "title": "Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23526464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14453,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, thyroid medullary carcinoma cells harboring RET C634W were sensitive to treatment with Selpercatinib (LOXO-292), demonstrating decreased cell proliferation in culture and inhibition of tumor growth in cell line xenograft models (PMID: 29912274).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11635,
                    "pubMedId": 29912274,
                    "title": "Selective RET kinase inhibition for patients with RET-altered cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29912274"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1766,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture (PMID: 17664273).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 589,
                    "pubMedId": 17664273,
                    "title": "Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17664273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5153,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 3761,
                "therapyName": "XMD15-44",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4887,
                    "pubMedId": 26046350,
                    "title": "Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26046350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5154,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 3274,
                "therapyName": "ALW-II-41-27",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4887,
                    "pubMedId": 26046350,
                    "title": "Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26046350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13494,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited Ret signaling and proliferation of a medullary thyroid cancer cell line harboring RET C634W in culture, and inhibited tumor growth in xenograft models (PMID: 29657135).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11101,
                    "pubMedId": null,
                    "title": "BLU-667 is a potent and highly selective RET inhibitor being developed for RET-driven cancers",
                    "url": "http://mct.aacrjournals.org/content/17/1_Supplement/B151"
                },
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8075,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a thyroid cancer cell line harboring RET C634W in culture (PMID: 23056499).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 652,
                "therapyName": "AZD1480",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6545,
                    "pubMedId": 23056499,
                    "title": "AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23056499"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7720,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Stivarga (regorafenib) inhibited proliferation of thyroid cancer cells harboring RET C634W in culture (PMID: 21170960).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 318,
                    "pubMedId": 21170960,
                    "title": "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21170960"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2192,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and inhibited tumor growth in cell line xenograft models of medullary thyroid carcinoma harboring RET C634W (PMID: 16507829).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2736,
                    "pubMedId": 16507829,
                    "title": "BAY 43-9006 inhibition of oncogenic RET mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16507829"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1779,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited phosphorylation of RET C634W and decreased tumor growth in xenograft models of a human thyroid carcinoma cell line harboring RET C634W mutation (PMID: 23705946).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3963,
                "name": "thyroid gland carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2039,
                    "pubMedId": 23705946,
                    "title": "In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23705946"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1894,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lenvima (lenvatinib) inhibited RET phosphorylation and signaling in thyroid cancer cells expressing RET C634W (PMID: 25295214).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2207,
                    "pubMedId": 25295214,
                    "title": "Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25295214"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5155,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).",
            "molecularProfile": {
                "id": 3188,
                "profileName": "RET C634W"
            },
            "therapy": {
                "id": 3762,
                "therapyName": "HG-6-63-01",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4887,
                    "pubMedId": 26046350,
                    "title": "Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26046350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8334,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803).",
            "molecularProfile": {
                "id": 26230,
                "profileName": "KDR pos RET C634W"
            },
            "therapy": {
                "id": 824,
                "therapyName": "Motesanib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 996,
                    "pubMedId": 21422803,
                    "title": "Anti-tumor activity of motesanib in a medullary thyroid cancer model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21422803"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3188,
            "profileName": "RET C634W",
            "profileTreatmentApproaches": [
                {
                    "id": 1223,
                    "name": "RET Inhibitor",
                    "profileName": "RET C634W"
                }
            ]
        },
        {
            "id": 26230,
            "profileName": "KDR pos RET C634W",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 125237,
            "transcript": "NM_020975",
            "gDna": "chr10:g.43114502C>G",
            "cDna": "c.1902C>G",
            "protein": "p.C634W",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 125238,
            "transcript": "NM_020630",
            "gDna": "chr10:g.43114502C>G",
            "cDna": "c.1902C>G",
            "protein": "p.C634W",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}